Proceeding contribution from Baroness Merron (Labour) in the House of Lords on Monday, 10 February 2025. It occurred during Ministerial statement on National Cancer Plan.
National Cancer Plan
I wish my noble friend well with his treatment. Screening for prostate cancer is not currently recommended in the UK because of the inaccuracy of the current best test available, which is the PSA. The advice we are given is that the PSA-based screening programme could harm men, as some could be diagnosed with a cancer that would not have caused them problems during their life; equally, some cancers may be missed. That is why we are investing £16 million towards the Prostate Cancer UK-led TRANSFORM programme, which is the name of the screening trial. On health inequalities, as I mentioned earlier, the trial is seeking to find better ways to detect prostate cancer, which is necessary, and to address the health inequalities.
Secondary information
- Type
- Proceeding contribution
- Reference
- 843 c1015
- Session
- 2024-26
- Chamber / Committee
- House of Lords chamber
- Subjects
- Breast cancer Cancer Hospitals Health services Public consultation Standards Waiting lists Screening Radiology Artificial intelligence Children and Young People Cancer Taskforce
- Link
- View this Proceeding contribution on hansard.parliament.uk
Librarians' tools
- Timestamp
- 2025-09-05 21:15:08 +0100
- URI
- http://hansard.intranet.data.parliament.uk/Lords/2025-02-10/25021012000154
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://hansard.intranet.data.parliament.uk/Lords/2025-02-10/25021012000154
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://hansard.intranet.data.parliament.uk/Lords/2025-02-10/25021012000154